Key Takeaways
- An investor group led by EQT has completed its exit from Galderma through a $6.3 billion share sale.
- The sale is part of the “Project Indigo” strategy after acquiring Galderma from Nestlé in 2019.
- Galderma’s shares have increased by over 180% since its IPO, driven by strong product demand.
Investor Exit from Galderma
A consortium led by EQT has successfully exited its remaining stake in Swiss skincare company Galderma through a significant share sale amounting to 4.89 billion Swiss francs (approximately US$6.3 billion). This transaction marks the completion of their exit strategy, referred to internally as “Project Indigo.”
The investors, which include the Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte, backed by Singapore’s GIC, initially acquired Galderma from Nestlé in 2019 for about 10.2 billion francs, inclusive of debt. Since then, they have steadily sold their shares as part of their divestment plan, which included Galderma’s 2024 IPO and subsequent share offerings.
Overall, the consortium has realized over 20 billion francs in proceeds from this investment. Galderma has witnessed a notable rise in share price, exceeding 180% since its public offering. This impressive performance has been underpinned by robust financial results and strong demand for popular products, particularly the skincare line Cetaphil and the injectable dermatitis treatment Namluvo.
This exit showcases a fruitful cycle for private equity investments, capitalizing on Galderma’s successful public listing and its upward trajectory in share value.
The content above is a summary. For more details, see the source article.
